This week, seven Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

TG Therapeutics Inc’s (NASDAQ:TGTX) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). For more information, get Portfolio Grader’s complete analysis of TGTX stock.

This week, Kamada Ltd. (NASDAQ:KMDA) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Shares of KMDA have increased 9.4% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of KMDA stock.

This week, Ariad Pharmaceuticals’ (NASDAQ:ARIA) ratings are up from a C last week to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

This is a strong week for Neurocrine Biosciences (NASDAQ:NBIX). The company’s rating climbs to B from the previous week’s C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

Array BioPharma (NASDAQ:ARRY) improves from a C to a B rating this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Wall Street has pushed the stock higher by 32% over the past month. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

Celldex Therapeutics (NASDAQ:CLDX) earns an A this week, jumping up from last week’s grade of B. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Wall Street seems to agree with the upgrade and has propelled the stock up 7.1% over the past month. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

Insmed Inc.’s (NASDAQ:INSM) ratings are looking better this week, moving up to a B from last week’s C. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.